{"nctId":"NCT04225260","briefTitle":"Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines","startDateStruct":{"date":"2020-01-27","type":"ACTUAL"},"conditions":["Glabellar Lines","Lateral Canthal Lines"],"count":902,"armGroups":[{"label":"QM1114-DP in the LCL and the GL areas","type":"EXPERIMENTAL","interventionNames":["Biological: botulinum toxin neuromodulator"]}],"interventions":[{"name":"botulinum toxin neuromodulator","otherNames":["QM1114-DP"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Male or female at least 18 years of age.\n\nExclusion Criteria:\n\n* Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.\n* Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than the investigational product).\n* Female who is pregnant, breast feeding, or intends to conceive a child during the study.\n* Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown","description":"4-point scale","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"769","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the LCL Investigator Scales at Maximum Smile","description":"4-point scale","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"719","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":902},"commonTop":["Injection site Pain","Injection site bruising","Headache","COVID-19","Hypertension"]}}}